The finding of NF-kB pathway activation after 17AAG treatment significantly associated to resistant cell lines suggests that simultaneous use of anti-tumor agents that block NF-κB activity together with HSP90 inhibitors may have a greater therapeutic value. Here, NFKB1 is linked to neoplasm.